Online inquiry

IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13501MR)

This product GTTS-WQ13501MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13501MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14346MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ10317MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ604MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ5698MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ12005MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ1472MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ16012MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ993MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW